GLRA1
Glycine receptor subunit alpha-1
As of the edition of 20 October 2026, GLRA1 (glycine receptor subunit alpha-1, UniProt P23415) has 6 drugs tested at it and 8 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23415
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 9
- Disease areas
- Nervous system; Heart and blood vessels; Mental health; Cancer; Lungs and airways; Urinary and reproductive; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 412
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sevoflurane | Marketed | Phase 4 | none listed |
| Desflurane | Marketed | Phase 4 | none listed |
| Isoflurane | Marketed | Phase 4 | none listed |
| Methoxyflurane | Marketed | Phase 4 | none listed |
| Enflurane | Marketed | No phase stated | none listed |
| Halothane | Marketed | No phase stated | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 6 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| AbbVie | Route B |
| Baxter Healthcare | Route B |
The other 6 companies at GLRA1
In the product8 companies in all; 6 are not named here, and no score is.
See the 8 companies at GLRA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.